ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2025
Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review
- Burden of Hospitalized Respiratory Syncytial Virus in Children in Sweden: A Population-based Case-cohort Study (2006-2023).The Pediatric infectious disease journal · 2026Article
- Nirsevimab effectiveness, number needed to immunize and impact on severe RSV outcomes, a test-negative study in Quebec, Canada.Lancet regional health. Americas · 2026Article
- Two-season effectiveness of a single nirsevimab dose against RSV hospitalisation in healthy term-born infants: a population-based case-control study, Spain, October 2023 to March 2025.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Reduced Emergency Department Visits and Hospitalizations in Infants after Universal Respiratory Syncytial Virus Immunization, Italy, 2024-25.Emerging infectious diseases · 2026Article
- [Nirsevimab immunization effectiveness against respiratory syncytial virus hospitalization in newborns: two season of use in Navarre, Spain].Anales del sistema sanitario de Navarra · 2025Article
- Beyond the first breath: comprehensive respiratory syncytial virus prevention through maternal immunization and infant immunoprophylaxis.Asian biomedicine : research, reviews and news · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using real-life data from Spain between October 2023 and March 2024, the number needed to immunise (NNI) with nirsevimab and the cost to prevent one RSV hospitalisation were estimated at 90 infants (95% CI: 77-108) and 19,700 EUR for catch-up immunisation, and 41 infants (95% CI: 35-50) and 9,000 EUR for at-birth immunisation. By month of birth, NNI and cost were lowest in infants born shortly before the RSV epidemic peak, with impact decreasing gradually for earlier or later births.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.